Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-17

Clinical Trial Update: Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of Provenge (sipuleucel-T) with or without pTVG-HP DNA booster vaccine in prostate cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PROVENGE (sipuleucel-T)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-07-17